{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:29:47Z","timestamp":1761863387342,"version":"build-2065373602"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T00:00:00Z","timestamp":1414108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,2,15]]},"abstract":"<jats:p>Clinical trials of chronic myeloid leukemia frequently rely on molecular markers as surrogates for clinical endpoints. Studies suggest that early molecular response (EMR) is a good indicator of a favorable prognosis and yet, to the authors' knowledge, the use of EMR as a robust surrogate marker for clinical response has yet to be fully explored. EMR to therapy appears to be affected by a variety of factors, including disease characteristics, risk score, adherence to treatment, and off\u2010target effects of the treatment. Therefore, although molecular markers improve important research, they also bring with them important questions regarding their reliability. To be useful, markers must be must be easily measureable, capable of generating meaningful data, and clinically relevant. <jats:italic>BCR\u2010ABL1<\/jats:italic> is the hallmark marker in chronic myeloid leukemia. Nevertheless, investigators still struggle with how best to measure and interpret both high and very low <jats:italic>BCR\u2010ABL1<\/jats:italic> levels. Statistical models of <jats:italic>BCR\u2010ABL1<\/jats:italic> kinetics must address these concerns and account for the <jats:italic>BCR\u2010ABL1<\/jats:italic> variability between and within patients. Response models should also incorporate disease characteristics and other important parameters. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:490\u2013497.<\/jats:bold> \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p>","DOI":"10.1002\/cncr.29053","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T06:17:27Z","timestamp":1414649847000},"page":"490-497","source":"Crossref","is-referenced-by-count":14,"title":["Analyzing molecular response in chronic myeloid leukemia clinical trials: Pitfalls and golden rules"],"prefix":"10.1002","volume":"121","author":[{"given":"Jo\u00eblle","family":"Guilhot","sequence":"first","affiliation":[{"name":"INSERM Clinical Investigation Center 1402 Poitiers University Poitiers France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"Hematology Laboratory Biology and Pathology Center Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Leukemic Hematopoiesis Laboratory and Therapeutic Target Victor S\u00e9galen University, INSERM U1035, Bordeaux University Medical Center Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"additional","affiliation":[{"name":"INSERM Clinical Investigation Center 1402 Poitiers University Poitiers France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,24]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26280"},{"volume-title":"National Comprehensive Cancer Network Guideline Inc. Version 3. CML Guidelines","year":"2014","key":"e_1_2_4_3_1"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-383711"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-150680"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291641"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2013.05.010"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403136"},{"key":"e_1_2_4_12_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.253.253","article-title":"Optimizing early prediction of outcome in CML using the exact decline of BCR\u2010ABL transcript levels within 3 months of imatinib treatment as a prognostic marker [abstract]","volume":"122","author":"Hanfstein B","year":"2013","journal-title":"Blood"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.908"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.104"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12618"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0258(20001115)19:21<3005::AID-SIM592>3.0.CO;2-9"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25604"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-140"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23508"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.116"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/b97377"},{"key":"e_1_2_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4264"},{"key":"e_1_2_4_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.772607"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5403"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.43"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.07.004"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12183"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0190-1"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.695779"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/biom.12071"},{"key":"e_1_2_4_42_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.168.168","article-title":"Relationship between molecular responses and disease progression in patients treated first line with imatinib based regimens: impact of treatment arm within the French Spirit Trial from the French CML Group (FI LMC) [abstract]","volume":"120","author":"Rousselot P","year":"2012","journal-title":"Blood"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1988"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.01.033"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.5797"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29053","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:59:52Z","timestamp":1760277592000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,24]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,2,15]]}},"alternative-id":["10.1002\/cncr.29053"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29053","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2014,10,24]]}}}